Colorectal Cancer Coverage from Every Angle
Advertisement
Advertisement

Thierry André, MD, on KEYNOTE-177: Clinical Implications of Pembrolizumab vs Chemotherapy in Metastatic Colorectal Cancer

Posted: Monday, June 15, 2020

Thierry André, MD, of Hôpital Saint-Antoine, reports the phase III trial results of the KEYNOTE-177 study, showing pembrolizumab doubled progression-free survival compared with chemotherapy in patients with microsatellite instability–high/mismatch repair–deficient metastatic disease, and elaborates on the duration of response with the immune checkpoint inhibitor.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.
Advertisement
Advertisement